7 Pulmonology Headlines You Missed in January 2026

Pulmonology research and clinical practice opened 2026 with momentum across drug development, guideline refinement, and diagnostic innovation. Early‑phase data in idiopathic pulmonary fibrosis (IPF) highlighted encouraging biologic and mechanistic signals—most notably with GRI‑0621 and the STAT3 inhibitor TTI‑101—while new evidence reframed conversations about bronchodilator responsiveness, positioning it as a powerful prognostic marker rather than a diagnostic divider. At the same time, the FDA’s clearance of LEADOPTIK’s high‑resolution biopsy system underscored a growing emphasis on real‑time precision in lung cancer diagnostics, a critical step as screening programs continue to expand.